Press Releases

INCLINE VILLAGE, Nev., April 27, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its first quarter financial results for the period ended March 31, 2012 on Thursday, May 3, 2012 after the markets close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern ...

INCLINE VILLAGE, Nev., April 12, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company will hold its annual meeting of stockholders on Tuesday, June 5, 2012, at 10:00 a.m. Pacific Time for all stockholders of record on April 13, 2012. The meeting will take place at the Hyatt Regency Hotel in Incline Village,...

INCLINE VILLAGE, Nev., March 8, 2012 /PRNewswire/ --PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced royalty revenue guidance for the first quarter ending March 31, 2012, of approximately $77 million, as compared with actual royalty revenue of $73 million for the first quarter of 2011, a five percent increase.  Total revenue for the first q...

INCLINE VILLAGE, Nev., Feb. 23, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the fourth quarter and full year ended December 31, 2011. (Logo:  http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) Total revenues in 2011 were $362 million, compared to $345 million in 2010, with royalty ...

INCLINE VILLAGE, Nev., Feb. 16, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its fourth quarter and full year financial results for the period ended December 31, 2011 on Thursday, February 23, 2012 after market close. PDL's management will host a conference call and webcast that day at ...

INCLINE VILLAGE, Nev., Feb. 2, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has entered into separate privately negotiated exchange agreements under which it has retired $10,028,000 aggregate principal amount of the Company's 2.875% Convertible Senior Notes due February 15, 2012 (the Old Notes). Pursuant to ...

INCLINE VILLAGE, Nev., Jan. 5, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced the settlement and final results of its offer to exchange up to $180,000,000 in aggregate principal amount of outstanding 2.875% Convertible Senior Notes due 2015 (Old Notes), for a like principal amount of new 2.875% Series 2012 Convertible...

INCLINE VILLAGE, Nev., Jan. 3, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced the expiration and preliminary results of its offer to exchange up to $180,000,000 in aggregate principal amount of outstanding 2.875% Convertible Senior Notes due 2015 (Old Notes), for a like principal amount of new 2.875% Series 2012 Conve...

INCLINE VILLAGE, Nev., Dec. 15, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the December 15, 2011, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of December 8, 2011, the record date. (Logo: http://photos.prnewswire.com/prnh/20110822/SF5580...

INCLINE VILLAGE, Nev., Dec. 12, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today corrected its earlier-announced adjusted conversion rate for its: 2.875% Convertible Senior Notes due February 15, 2015 (February 2015 Notes), to 155.396 shares of common stock per $1,000 principal amount, reflecting a conversion price of ...